FAQs

  1. What is FIBRICOR®?

    FIBRICOR is a prescription medicine used to treat cholesterol in the blood by lowering the total amount of triglycerides and bad cholesterol (LDL) and increasing the good cholesterol (HDL). You should be on a low-fat and low-cholesterol  diet while you take FIBRICOR.

  2. How should I take FIBRICOR?

    You should be on a low-fat and low-cholesterol diet while you take FIBRICOR. FIBRICOR should be taken once a day, with or without food, as prescribed by your doctor. FIBRICOR should be swallowed whole with water.

  3. What are the possible side effects of FIBRICOR?

    The most common side effects with FIBRICOR include headache, abdominal pain, back pain, and increases in liver enzymes that are measured by blood tests. Tell your doctor if you have any side effect that bothers you or does not go away.

  4. Who should not take FIBRICOR?

    FIBRICOR should not be taken by people with liver, gallbladder, or severe kidney disease, nursing mothers, or those allergic to any product ingredient.

  5. Will FIBRICOR be affordable?

    No one should have to go without medicine prescribed by their physician due to financial reasons. Many insurance plans have made FIBRICOR available at the low cost of a generic. If your plan is not listed, you can receive a discount on your FIBRICOR prescription.

Important Safety Information HCP

FIBRICOR® is contraindicated in patients with severe renal impairment including those on dialysis, with active liver disease including primary biliary cirrhosis and unexplained persistent liver function abnormalities and with gallbladder disease. FIBRICOR is also contraindicated in nursing mothers and patients with hypersensitivity to fenofibric acid, choline fenofibrate or fenofibrate.

The most commonly reported adverse reactions (> 2% and greater than placebo) are increases in liver test values, abdominal pain, back pain, and headache.

Fenofibrate can increase serum transaminases, so patients should be monitored for AST or ALT changes periodically for the duration of the therapy. In addition, myopathy and rhabdomyolysis have been reported in patients taking fenofibrate. The risks of myopathy and rhabdomyolysis may be increased in patients who are elderly, have diabetes, renal failure, or hypothyroidism. Patients should be advised to report unexplained muscle pain, tenderness or weakness promptly, especially if accompanied by malaise or fever. Creatine phosphokinase (CPK) levels should be assessed in these patients. Fenofibrate can reversibly increase serum creatinine levels. Patients with renal impairment and those at risk for renal insufficiency should be periodically monitored. Fenofibrate increases cholesterol excretion into the bile, leading to risk of cholelithiasis. If cholelithiasis is suspected, gallbladder studies are indicated.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088.

References: 1. Data on file, URL Pharma, Inc. 2. Fibricor [package insert]. Philadelphia, PA: URL Pharma, Inc.; 2009. 3. Trilipix [package insert]. North Chicago, IL: Abbott Laboratories; 2008. 4. TriCor [package insert]. North Chicago, IL: Abbott Laboratories; 2008. 5. Dorland's Illustrated Medical Dictionary. 28th ed. Philadelphia, PA: W.B. Saunders Company; 1994.

TriCor® and Trilipix® are registered trademarks of Fournier Industrie et Santé Corporation, France.